Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Neoplasm progression? 1,276 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,276 reports of Neoplasm progression have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 1.5% of all adverse event reports for DOXORUBICIN.

1,276
Reports of Neoplasm progression with DOXORUBICIN
1.5%
of all DOXORUBICIN reports
371
Deaths
295
Hospitalizations

How Dangerous Is Neoplasm progression From DOXORUBICIN?

Of the 1,276 reports, 371 (29.1%) resulted in death, 295 (23.1%) required hospitalization, and 58 (4.5%) were considered life-threatening.

Is Neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 1,276 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Neoplasm progression?

PALBOCICLIB (10,885) SUNITINIB MALATE (1,920) CYCLOPHOSPHAMIDE (1,588) CARBOPLATIN (1,370) AXITINIB (1,315) LETROZOLE (1,225) PACLITAXEL (1,180) CRIZOTINIB (1,161) VINCRISTINE (1,106) GEMCITABINE (960)

Which DOXORUBICIN Alternatives Have Lower Neoplasm progression Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Neoplasm progression Reports All Drugs Causing Neoplasm progression DOXORUBICIN Demographics